Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Suven Pharma
Join Channel
Consolidated Standalone

Suven Pharma

₹636.5 -9 | 1.4%

Market Cap ₹16203 Cr.

Stock P/E 43.7

P/B 8.2

Current Price ₹636.5

Book Value ₹ 77.9

Face Value 1

52W High ₹767

Dividend Yield 0.94%

52W Low ₹ 427.1

Edit Ratio

Suven Pharma Research see more...

Overview Inc. Year: 2018Industry: Pharmaceuticals & Drugs

Suven Pharmaceuticals Ltd operates as a bio-pharmaceutical organization in India, USA, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based totally intermediates, active pharmaceutical substances, specialty chemicals, and formulated capsules beneath contract studies and production offerings for pharmaceutical, biotechnology, and chemical agencies. The organisation was established in 2018 and is based totally in Hyderabad, India. Suven Pharmaceuticals Ltd is a subsidiary of Jasti Property and Equity Holdings Private Ltd.

Read More..

Suven Pharma Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Suven Pharma Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 301 392 364 339 278 354 369 348 231 220
Other Income 5 65 17 11 11 13 11 11 20 14
Total Income 306 456 381 350 289 367 381 358 251 234
Total Expenditure 179 206 207 188 179 207 200 181 133 155
Operating Profit 127 251 174 162 111 160 180 178 118 79
Interest 1 1 2 1 0 1 2 1 1 1
Depreciation 9 11 10 12 12 12 12 13 12 13
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 116 239 161 149 98 146 166 164 105 65
Provision for Tax 37 79 70 41 26 38 42 43 26 19
Profit After Tax 80 160 92 108 72 108 124 121 80 47
Adjustments 17 0 0 0 -0 0 0 0 0 0
Profit After Adjustments 97 160 92 108 72 108 124 121 80 47
Adjusted Earnings Per Share 3.8 6.3 3.6 4.2 2.8 4.2 4.9 4.7 3.1 1.8

Suven Pharma Profit & Loss

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 378 834 1010 1320 1340 1168
Other Income 1 18 14 92 46 56
Total Income 378 852 1024 1413 1387 1224
Total Expenditure 206 449 567 739 766 669
Operating Profit 172 403 457 674 620 555
Interest 3 23 12 9 13 5
Depreciation 11 24 32 39 48 50
Exceptional Income / Expenses 0 0 0 0 0 0
Profit Before Tax 158 405 468 668 560 500
Provision for Tax 49 88 105 214 148 130
Profit After Tax 109 317 362 454 411 372
Adjustments 0 0 0 0 0 0
Profit After Adjustments 109 317 362 454 411 372
Adjusted Earnings Per Share 0 12.5 14.2 17.8 16.2 14.5

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 2% 17% 0% 0%
Operating Profit CAGR -8% 15% 0% 0%
PAT CAGR -9% 9% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 34% 6% NA% NA%
ROE Average 25% 32% 32% 32%
ROCE Average 33% 40% 39% 39%

Suven Pharma Balance Sheet

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 590 845 1181 1527 1735
Minority's Interest 0 0 0 0 0
Borrowings 0 91 36 28 5
Other Non-Current Liabilities 35 36 38 64 67
Total Current Liabilities 191 320 322 348 303
Total Liabilities 816 1292 1576 1967 2110
Fixed Assets 271 357 441 534 663
Other Non-Current Assets 122 424 469 167 291
Total Current Assets 423 511 667 1265 1155
Total Assets 816 1292 1576 1967 2110

Suven Pharma Cash Flow

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 0 11 12 7 45
Cash Flow from Operating Activities 50 407 383 330 451
Cash Flow from Investing Activities -65 -413 -311 -136 -195
Cash Flow from Financing Activities 26 7 -76 -156 -236
Net Cash Inflow / Outflow 11 1 -5 37 20
Closing Cash & Cash Equivalent 11 12 7 45 65

Suven Pharma Ratios

# Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 0 12.45 14.23 17.83 16.16
CEPS(Rs) 0 13.38 15.48 19.36 18.03
DPS(Rs) 0 5 2 5 6
Book NAV/Share(Rs) 0 33.18 46.39 59.99 68.16
Core EBITDA Margin(%) 45.4 46.15 43.87 44.03 42.78
EBIT Margin(%) 42.52 51.28 47.47 51.18 42.68
Pre Tax Margin(%) 41.78 48.51 46.32 50.53 41.72
PAT Margin (%) 28.92 38.02 35.89 34.35 30.66
Cash Profit Margin (%) 31.96 40.84 39.02 37.31 34.22
ROA(%) 13.39 30.07 25.26 25.62 20.18
ROE(%) 18.92 44.58 35.78 33.52 25.21
ROCE(%) 23.87 50.21 40.76 45.92 33.41
Receivable days 142.49 57.94 39.69 46.8 47.25
Inventory Days 151.76 72.66 67.95 66.93 81.11
Payable days 192.73 100.95 94.44 87.45 77.47
PER(x) 0 8.09 34.8 34.66 29.26
Price/Book(x) 0 3.04 10.68 10.3 6.93
Dividend Yield(%) 0 2.48 0.4 0.81 1.27
EV/Net Sales(x) 0 3.28 12.62 11.95 8.98
EV/Core EBITDA(x) 0 6.79 27.87 23.41 19.4
Net Sales Growth(%) 0 120.68 21.1 30.75 1.52
EBIT Growth(%) 0 166.14 12.11 41.05 -15.32
PAT Growth(%) 0 190.1 14.3 25.24 -9.37
EPS Growth(%) 0 0 14.3 25.24 -9.37
Debt/Equity(x) 0.14 0.22 0.12 0.06 0.04
Current Ratio(x) 2.22 1.6 2.07 3.64 3.81
Quick Ratio(x) 1.39 1.05 1.45 2.82 2.78
Interest Cover(x) 57.6 18.54 41.09 79.29 44.69
Total Debt/Mcap(x) 0 0.07 0.01 0.01 0.01

Suven Pharma Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 60 60 60 60 60 60 60 60 60 50.1
FII 8.25 8.56 8.49 7.58 8.1 9.47 9.5 10.01 10.14 9.54
DII 5.94 6.56 6.96 10.87 11.36 11.43 10.63 14.14 15.95 17.25
Public 25.82 24.88 24.55 21.55 20.53 19.1 19.87 15.84 13.91 23.1
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 32%
  • Debtor days have improved from 87.45 to 77.47days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 8.2 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Suven Pharma News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!